Related Experiment Video
Updated: Jun 17, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Pyruvate dehydrogenase E2 deficiency: a potentially treatable cause of episodic dystonia
Catherine A McWilliam1, Cheryl K Ridout, Ruth M Brown
1Ferguson Smith Centre for Clinical Genetics, Yorkhill Hospital, Dalnair Street, Glasgow, G3 8SJ, UK. cmcwilliam1@nhs.net
Abstract:
The association of progressive episodic dystonia and learning disability with distinctive neuroimaging findings may lead to consideration of atypical Pantothenate Kinase Associated Neurodegeneration (PKAN) and investigations directed towards that diagnosis. Recent reports indicate that deficiency of dihydrolipoamide acetyltransferase, the E2 component of the pyruvate dehydrogenase complex, may present similarly, and that this disorder should also be considered in the differential diagnosis. We describe two sisters with early onset episodic dystonia and pyruvate dehydrogenase deficiency caused by defects in the E2 subunit. Both have neuroimaging features similar to previously described patients and have mutations in the DLAT gene. As this condition is potentially treatable with a ketogenic diet, the possibility of this diagnosis should be considered in similar cases.
Related Concept Videos
Alterations in Muscle Tone ll
Inborn Errors of Metabolism
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
Tetanus
Lysosomal Hydrolases
